{
    "xml": "<topic id=\"PHP5529\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/erlotinib\" basename=\"erlotinib\" title=\"ERLOTINIB\">\n<title>ERLOTINIB</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1048\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/protein-kinase-inhibitors/erlotinib\">Erlotinib</xref>\n</p>\n<data name=\"vtmid\">414122006</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_208007314\" title=\"Protein kinase inhibitors\">Protein kinase inhibitors</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP63766\" outputclass=\"drugAction\" rev=\"1.8\" parent=\"/drugs/erlotinib\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Erlotinib is a tyrosine kinase inhibitor.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63689\" outputclass=\"indicationsAndDose\" rev=\"1.13\" parent=\"/drugs/erlotinib\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of locally advanced or metastatic non-small cell lung cancer after failure of previous chemotherapy</p>\n<p outputclass=\"therapeuticIndication\">Monotherapy for maintenance treatment of locally advanced or metastatic non-small cell lung cancer with stable disease after four cycles of platinum-based chemotherapy</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>150&#8239;mg once daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of metastatic pancreatic cancer (in combination with gemcitabine)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>100&#8239;mg once daily.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63774\" outputclass=\"importantSafetyInformation\" rev=\"1.10\" parent=\"/drugs/erlotinib\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis (May 2012)</p>\n<p>Keratitis and ulcerative keratitis have been reported following treatment with epidermal growth factor receptor (EGFR) inhibitors for cancer (cetuximab, erlotinib, gefitinib and panitumumab). In rare cases, this has resulted in corneal perforation and blindness. Patients undergoing treatment with EGFR inhibitors who present with acute or worsening signs and symptoms suggestive of keratitis should be referred promptly to an opthalmology specialist. Treatment should be interupted or discontinued if ulcerative keratitis is diagnosed.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Risks of incorrect dosing of oral anti-cancer medicines</p>\n<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.</p>\n<p>Standards to be followed to achieve this include:</p>\n<ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>\n</ul>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63804\" outputclass=\"cautions\" rev=\"1.16\" parent=\"/drugs/erlotinib\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Smoking</p>\n<p>Dose adjustment may be necessary if smoking started or stopped during treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63683\" outputclass=\"interactions\" rev=\"1.10\" parent=\"/drugs/erlotinib\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Caution with concomitant use with hepatotoxic drugs&#8212;monitor liver function.</p>\n<p>Appendix 1 (erlotinib).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63615\" outputclass=\"sideEffects\" rev=\"1.14\" parent=\"/drugs/erlotinib\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Abdominal pain</ph>; <ph outputclass=\"sideEffect\">anorexia</ph>; <ph outputclass=\"sideEffect\">conjunctivitis</ph>; <ph outputclass=\"sideEffect\">depression</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">dry skin</ph>; <ph outputclass=\"sideEffect\">dyspepsia</ph>; <ph outputclass=\"sideEffect\">fatigue</ph>; <ph outputclass=\"sideEffect\">flatulence</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">neuropathy</ph>; <ph outputclass=\"sideEffect\">pruritus</ph>; <ph outputclass=\"sideEffect\">rigor</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Eyelash changes</ph>; <ph outputclass=\"sideEffect\">gastro-intestinal perforation</ph>; <ph outputclass=\"sideEffect\">interstitial lung disease&#8212;discontinue if unexplained symptoms such as dyspnoea, cough or fever occur</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Hepatic failure</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"veryRare\">\n<p outputclass=\"title\">Very rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Corneal perforation</ph>; <ph outputclass=\"sideEffect\">corneal ulceration</ph>; <ph outputclass=\"sideEffect\">Stevens-Johnson syndrome</ph>; <ph outputclass=\"sideEffect\">toxic epidermal necrolysis</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">bone-marrow suppression</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">oral mucositis</ph>; <ph outputclass=\"sideEffect\">thromboembolism</ph>; <ph outputclass=\"sideEffect\">tumour lysis syndrome</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63795\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/erlotinib\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Exclude pregnancy before treatment with cytotoxic drugs.</p>\n<p>Contraceptive advice should be given before cytotoxic therapy begins)&#8212;effective contraception required during and for at least 2 weeks after treatment.</p>\n<p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63672\" outputclass=\"pregnancy\" parent=\"/drugs/erlotinib\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;toxicity in <i>animal</i> studies.</p>\n<p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p>\n<p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63815\" outputclass=\"breastFeeding\" parent=\"/drugs/erlotinib\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid- no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63750\" outputclass=\"hepaticImpairment\" parent=\"/drugs/erlotinib\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution in mild to moderate impairment.</p>\n<p>Avoid in severe impairment.</p>\n<p>Monitor liver function in pre-existing liver disease.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63638\" outputclass=\"renalImpairment\" parent=\"/drugs/erlotinib\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63346\" outputclass=\"nationalFunding\" rev=\"1.20\" parent=\"/drugs/erlotinib\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA162</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Erlotinib for non-small-cell lung cancer (November 2008)</p>\r\n<p>Erlotinib is recommended, as an alternative to docetaxel, as second-line treatment for locally advanced or metastatic non-small-cell lung cancer after failure of previous chemotherapy, on the basis that it is provided by the manufacturer at an overall treatment cost equal to that of docetaxel. Erlotinib is<b> not</b> recommended in patients for whom docetaxel is unsuitable or as third-line treatment after docetaxel.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA162\">www.nice.org.uk/TA162</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA227</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (June 2011)</p>\r\n<p>Erlotinib monotherapy is <b>not</b> recommended for maintenance treatment in people with locally advanced or metastatic non-small-cell lung cancer who have stable disease after platinum-based first-line chemotherapy.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA227\">www.nice.org.uk/TA227</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA258</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (June 2012)</p>\r\n<p>Erlotinib is recommended as an option for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer if:</p>\r\n<ul>\r\n<li>they test positive for the epidermal growth factor tyrosine kinase (EGFR-TK) mutation <b>and</b>\r\n</li>\r\n<li>the manufacturer provides erlotinib at the discounted price agreed under the patient access scheme (as revised in 2012).</li>\r\n</ul>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA258\">www.nice.org.uk/TA258</xref>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecisions\">\r\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The<i> Scottish Medicines Consortium</i> has advised (May 2006) that erlotinib (<i>Tarceva</i>\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland for the treatment of locally advanced or metastatic non-small cell lung cancer, after failure of at least one chemotherapy regimen. Erlotinib is restricted to use in patients who would otherwise be eligible for treatment with docetaxel monotherapy.</p>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has also advised (December 2011) that erlotinib (<i>Tarceva</i>\r\n<tm tmtype=\"reg\"/>) is accepted for use within NHS Scotland for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP5529-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/erlotinib\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75657\" title=\"Tablet\" namespace=\"/drugs/erlotinib/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1048\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/protein-kinase-inhibitors/erlotinib\" title=\"Erlotinib\" count=\"1\" rel=\"link\">Erlotinib</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75657\" namespace=\"/drugs/erlotinib/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP5529",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/erlotinib",
    "basename": "erlotinib",
    "title": "ERLOTINIB",
    "interactants": [
        {
            "id": "bnf_int_1048",
            "label": "Erlotinib"
        }
    ],
    "vtmid": "414122006",
    "drugClassification": [
        "Protein kinase inhibitors"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Erlotinib is a tyrosine kinase inhibitor.",
                "html": "<p>Erlotinib is a tyrosine kinase inhibitor.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of locally advanced or metastatic non-small cell lung cancer after failure of previous chemotherapy",
                        "html": "Treatment of locally advanced or metastatic non-small cell lung cancer after failure of previous chemotherapy"
                    },
                    {
                        "textContent": "Monotherapy for maintenance treatment of locally advanced or metastatic non-small cell lung cancer with stable disease after four cycles of platinum-based chemotherapy",
                        "html": "Monotherapy for maintenance treatment of locally advanced or metastatic non-small cell lung cancer with stable disease after four cycles of platinum-based chemotherapy"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "150 mg once daily.",
                        "html": "<p>150&#8239;mg once daily.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of metastatic pancreatic cancer (in combination with gemcitabine)",
                        "html": "Treatment of metastatic pancreatic cancer (in combination with gemcitabine)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "100 mg once daily.",
                        "html": "<p>100&#8239;mg once daily.</p>"
                    }
                ]
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis (May 2012)",
                "textContent": "Keratitis and ulcerative keratitis have been reported following treatment with epidermal growth factor receptor (EGFR) inhibitors for cancer (cetuximab, erlotinib, gefitinib and panitumumab). In rare cases, this has resulted in corneal perforation and blindness. Patients undergoing treatment with EGFR inhibitors who present with acute or worsening signs and symptoms suggestive of keratitis should be referred promptly to an opthalmology specialist. Treatment should be interupted or discontinued if ulcerative keratitis is diagnosed.",
                "html": "<p>Keratitis and ulcerative keratitis have been reported following treatment with epidermal growth factor receptor (EGFR) inhibitors for cancer (cetuximab, erlotinib, gefitinib and panitumumab). In rare cases, this has resulted in corneal perforation and blindness. Patients undergoing treatment with EGFR inhibitors who present with acute or worsening signs and symptoms suggestive of keratitis should be referred promptly to an opthalmology specialist. Treatment should be interupted or discontinued if ulcerative keratitis is diagnosed.</p>"
            },
            {
                "type": "importantSafetyInformation",
                "title": "Risks of incorrect dosing of oral anti-cancer medicines",
                "textContent": "The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.\n\nStandards to be followed to achieve this include:\n\nnon-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity; staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.",
                "html": "<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.</p><p>Standards to be followed to achieve this include:</p><ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>\n</ul>"
            }
        ]
    },
    "cautions": {
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "title": "Smoking",
                "textContent": "Dose adjustment may be necessary if smoking started or stopped during treatment.",
                "html": "<p>Dose adjustment may be necessary if smoking started or stopped during treatment.</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Caution with concomitant use with hepatotoxic drugs&#8212;monitor liver function.\n\nAppendix 1 (erlotinib).",
                "html": "<p>Caution with concomitant use with hepatotoxic drugs&#8212;monitor liver function.</p><p>Appendix 1 (erlotinib).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Abdominal pain",
                        "html": "Abdominal pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "anorexia",
                        "html": "anorexia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "conjunctivitis",
                        "html": "conjunctivitis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "depression",
                        "html": "depression",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dry skin",
                        "html": "dry skin",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dyspepsia",
                        "html": "dyspepsia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "fatigue",
                        "html": "fatigue",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "flatulence",
                        "html": "flatulence",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "neuropathy",
                        "html": "neuropathy",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "pruritus",
                        "html": "pruritus",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "rigor",
                        "html": "rigor",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Eyelash changes",
                        "html": "Eyelash changes",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "gastro-intestinal perforation",
                        "html": "gastro-intestinal perforation",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "interstitial lung disease&#8212;discontinue if unexplained symptoms such as dyspnoea, cough or fever occur",
                        "html": "interstitial lung disease&#8212;discontinue if unexplained symptoms such as dyspnoea, cough or fever occur",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Hepatic failure",
                        "html": "Hepatic failure",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "veryRare": [
                    {
                        "type": "veryRare",
                        "textContent": "Corneal perforation",
                        "html": "Corneal perforation",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "corneal ulceration",
                        "html": "corneal ulceration",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "Stevens-Johnson syndrome",
                        "html": "Stevens-Johnson syndrome",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "toxic epidermal necrolysis",
                        "html": "toxic epidermal necrolysis",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bone-marrow suppression",
                        "html": "bone-marrow suppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oral mucositis",
                        "html": "oral mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thromboembolism",
                        "html": "thromboembolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tumour lysis syndrome",
                        "html": "tumour lysis syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Exclude pregnancy before treatment with cytotoxic drugs.\n\nContraceptive advice should be given before cytotoxic therapy begins)&#8212;effective contraception required during and for at least 2 weeks after treatment.\n\nRegimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.",
                "html": "<p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given before cytotoxic therapy begins)&#8212;effective contraception required during and for at least 2 weeks after treatment.</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;toxicity in animal studies.\n\nMost cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.\n\nConsiderable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.",
                "html": "<p>Manufacturer advises avoid&#8212;toxicity in <i>animal</i> studies.</p><p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid- no information available.",
                "html": "<p>Manufacturer advises avoid- no information available.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution in mild to moderate impairment.\n\nAvoid in severe impairment.\n\nMonitor liver function in pre-existing liver disease.",
                "html": "<p>Manufacturer advises caution in mild to moderate impairment.</p><p>Avoid in severe impairment.</p><p>Monitor liver function in pre-existing liver disease.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid in severe impairment.",
                "html": "<p>Manufacturer advises avoid in severe impairment.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA162",
                        "label": "www.nice.org.uk/TA162"
                    }
                ],
                "fundingIdentifier": "NICE TA162",
                "textContent": "Erlotinib for non-small-cell lung cancer (November 2008) Erlotinib is recommended, as an alternative to docetaxel, as second-line treatment for locally advanced or metastatic non-small-cell lung cancer after failure of previous chemotherapy, on the basis that it is provided by the manufacturer at an overall treatment cost equal to that of docetaxel. Erlotinib is not recommended in patients for whom docetaxel is unsuitable or as third-line treatment after docetaxel.\n\nwww.nice.org.uk/TA162",
                "html": "<p outputclass=\"title\">Erlotinib for non-small-cell lung cancer (November 2008)</p> <p>Erlotinib is recommended, as an alternative to docetaxel, as second-line treatment for locally advanced or metastatic non-small-cell lung cancer after failure of previous chemotherapy, on the basis that it is provided by the manufacturer at an overall treatment cost equal to that of docetaxel. Erlotinib is<b> not</b> recommended in patients for whom docetaxel is unsuitable or as third-line treatment after docetaxel.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA162\">www.nice.org.uk/TA162</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA227",
                        "label": "www.nice.org.uk/TA227"
                    }
                ],
                "fundingIdentifier": "NICE TA227",
                "textContent": "Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (June 2011) Erlotinib monotherapy is not recommended for maintenance treatment in people with locally advanced or metastatic non-small-cell lung cancer who have stable disease after platinum-based first-line chemotherapy.\n\nwww.nice.org.uk/TA227",
                "html": "<p outputclass=\"title\">Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (June 2011)</p> <p>Erlotinib monotherapy is <b>not</b> recommended for maintenance treatment in people with locally advanced or metastatic non-small-cell lung cancer who have stable disease after platinum-based first-line chemotherapy.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA227\">www.nice.org.uk/TA227</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA258",
                        "label": "www.nice.org.uk/TA258"
                    }
                ],
                "fundingIdentifier": "NICE TA258",
                "textContent": "Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (June 2012) Erlotinib is recommended as an option for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer if: they test positive for the epidermal growth factor tyrosine kinase (EGFR-TK) mutation and the manufacturer provides erlotinib at the discounted price agreed under the patient access scheme (as revised in 2012).\n\nwww.nice.org.uk/TA258",
                "html": "<p outputclass=\"title\">Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (June 2012)</p> <p>Erlotinib is recommended as an option for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer if:</p> <ul> <li>they test positive for the epidermal growth factor tyrosine kinase (EGFR-TK) mutation <b>and</b> </li> <li>the manufacturer provides erlotinib at the discounted price agreed under the patient access scheme (as revised in 2012).</li> </ul><xref format=\"html\" href=\"http://www.nice.org.uk/TA258\">www.nice.org.uk/TA258</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75657",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1048",
                "label": "Erlotinib",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75657",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}